《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望

doi:10.16139/j.1007-9610.2020.01.002

外科理论与实践 ›› 2020, Vol. 25 ›› Issue (01): 6-9.doi: 10.16139/j.1007-9610.2020.01.002

《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望

黄成, 孙惠川()

复旦大学附属中山医院肝脏外科,上海 200032

收稿日期:2019-10-25 出版日期:2020-01-25 发布日期:2020-02-25
通讯作者: 孙惠川 E-mail:sun.huichuan@zs-hospital.sh.cn

Prospects for updates on the field of liver surgery in “Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma in China (2019 Edition)”

HUANG Cheng, SUN Huichuan()

Received:2019-10-25 Online:2020-01-25 Published:2020-02-25
Contact: SUN Huichuan E-mail:sun.huichuan@zs-hospital.sh.cn

摘要/Abstract

关键词: 肝癌, 诊疗规范, 手术切除, 肝移植

中图分类号:

R735.7

黄成, 孙惠川. 《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望[J]. 外科理论与实践, 2020, 25(01): 6-9.

HUANG Cheng, SUN Huichuan. Prospects for updates on the field of liver surgery in “Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma in China (2019 Edition)”[J]. Journal of Surgery Concepts & Practice, 2020, 25(01): 6-9.

参考文献 19

[1]	Mohkam K, Dumont PN, Manichon AF, et al. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm[J]. J Hepatol, 2018, 68(6):1172-1180.
[2]	Wei X, Jiang Y, Zhang X, et al. Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study[J]. J Clin Oncol, 2019, 37(24):2141-2151.
[3]	Xiao H, Zhang B, Mei B, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: a long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine (Baltimore), 2015, 94(7):e495.
[4]	Zhong JH, Ke Y, Gong WF, et al. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma[J]. Ann Surg, 2014, 260(2):329-340.
[5]	Chen X, Zhai J, Cai X, et al. Severity of portal hypertension and prediction of postoperative liver failure after li-ver resection in patients with Child-Pugh grade A cirrhosis[J]. Br J Surg, 2012, 99(12):1701-1710. doi: 10.1002/bjs.8951 pmid: 23132418
[6]	Li XL, Zhu XD, Cai H, et al. Postoperative alpha-fetoprotein response predicts tumor recurrence and survival after hepatectomy for hepatocellular carcinoma: A propensity score matching analysis[J]. Surgery, 2019, 165(6):1161-1167.
[7]	Yang J, Tao HS, Cai W, et al. Accuracy of actual resec-ted liver volume in anatomical liver resections guided by 3-dimensional parenchymal staining using fusion indocyanine green fluorescence imaging[J]. J Surg Oncol, 2018, 118(7):1081-1087.
[8]	Mise Y, Hasegawa K, Satou S, et al. How has virtual hepatectomy changed the practice of liver surgery? experience of 1194 virtual hepatectomy before Liver resection and living donor liver transplantation[J]. Ann Surg, 2018, 268(1):127-133.
[9]	Wu X, Huang Z, Lau WY, et al. Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching study[J]. Surg Endosc, 2019, 33(1):206-215.
[10]	Cheung TT, Han HS, She WH, et al. The Asia Pacific consensus statement on laparoscopic liver resection for hepatocellular carcinoma: a report from the 7th Asia-Pacific primary liver cancer expert meeting held in Hong Kong[J]. Liver Cancer, 2018, 7(1):28-39. doi: 10.1159/000481834 pmid: 29662831
[11]	Wang Z, Peng Y, Hu J, et al. Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus-related hepatocellular carcinoma: a single center study of 45 patients[J]. Ann Surg, 2018. Jul10.doi: 10.1097/SLA.0000000000002942.[Epub ahead of print] doi: 10.1097/SLA.0000000000002942 URL
[12]	He MK, Zou RH, Li QJ, et al. Phase Ⅱ study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis[J]. Cardiovasc Intervent Radiol, 2018, 41(5):734-743.
[13]	Yang P, Si A, Yang J, et al. A wide-margin liver resection improves long-term outcomes for patients with HBV-related hepatocellular carcinoma with microvascular invasion[J]. Surgery, 2019, 165(4):721-730.
[14]	Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study[J]. Clin Cancer Res, 2018, 24(9):2074-2081.
[15]	Wei W, Jian PE, Li SH, et al. Adjuvant transcatheter arterial chemoembolization after curative resection for he-patocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety[J]. Cancer Commun (Lond), 2018, 38(1):61.
[16]	Chen Q, Shu C, Laurence AD, et al. Effect of Huaier granule on recurrence after curative resection of HCC: a multicentre, randomised clinical trial[J]. Gut, 2018, 67(11):2006-2016.
[17]	Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(4):203-217. doi: 10.1038/nrgastro.2016.193 pmid: 28053342
[18]	Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis[J]. Hepatology, 2018, 67(1):381-400.
[19]	Pinheiro RS, Waisberg DR, Nacif LS, et al. Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?[J]. Transl Gastroenterol Hepatol, 2017, 2:68. doi: 10.21037/tgh.2017.08.02 pmid: 28905009

《原发性肝癌诊疗规范（2019年版）》肝脏外科领域更新的展望

Prospects for updates on the field of liver surgery in “Guidelines for Diagnosis and Treatment of Primary Hepatocellular Carcinoma in China (2019 Edition)”

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 19

相关文章 15

编辑推荐

Metrics

本文评价

[1]	叶枫, 龚笑勇, 任家俊, 蔡强, 陈胜. ERCP在原发性肝癌围术期胆道并发症诊治中的应用[J]. 外科理论与实践, 2023, 28(04): 355-360.
[2]	Chang Jessica, 陈旭晓, 陈拥军. 脾脏在肝癌合并肝硬化中的临床价值[J]. 外科理论与实践, 2023, 28(04): 394-398.
[3]	张辉, 龚玲, 郭茜, 罗艳. 肝癌全身麻醉射频消融术后应用舒更葡糖钠逆转神经肌肉阻滞的回顾性研究[J]. 外科理论与实践, 2023, 28(01): 72-76.
[4]	杨雪, 刘锦, 王铮, 陶杰, 郝杰, 李宇, 孙昊. 他克莫司降低肝移植病人ERCP术后胰腺炎发生的临床观察[J]. 外科理论与实践, 2022, 27(03): 253-255.
[5]	陈聪燕综述, 王俊青, 陈拥军审校. 肠道菌群与肝癌的发病机制[J]. 外科理论与实践, 2022, 27(03): 256-260.
[6]	孙惠川. 肝细胞癌转化治疗的现状与展望[J]. 外科理论与实践, 2022, 27(02): 134-138.
[7]	任家俊, 陈拥军. 肝脾联合切除治疗原发性肝癌合并门静脉高压及脾功能亢进[J]. 外科理论与实践, 2022, 27(02): 139-144.
[8]	吴浩翔, 吕子成, 侯宇宸, 张子杰, 乔子耘, 冯浩, 夏强. 儿童肝移植中他克莫司浓度个体内变异[J]. 外科理论与实践, 2022, 27(02): 145-151.
[9]	张磊, 毛家玺, 李涛, 滕飞, 孙克彦. 术前免疫炎症反应对原发性胆汁性胆管炎肝移植病人预后影响的双中心回顾性研究[J]. 外科理论与实践, 2022, 27(02): 158-164.
[10]	汤钊猷. 中华哲学思维对肝癌治疗的启迪[J]. 外科理论与实践, 2022, 27(02): 93-94.
[11]	朱鹏, 廖威, 张必翔, 陈孝平. 机器人肝癌肝切除应用现状与前景[J]. 外科理论与实践, 2022, 27(02): 95-99.
[12]	黄纪伟, 邱国腾, 曾勇. 肝细胞癌外科治疗进展[J]. 外科理论与实践, 2022, 27(02): 113-118.
[13]	冯浩, 吕子成, 夏强. 肝癌肝移植全过程管理及治疗进展[J]. 外科理论与实践, 2022, 27(02): 119-122.
[14]	曹君, 陈亚进. 腹腔镜解剖性肝切除治疗肝癌的规范与思考[J]. 外科理论与实践, 2022, 27(02): 123-127.
[15]	苏长青. 从基础研究到临床转化应用谈肝癌的诊治进展[J]. 诊断学理论与实践, 2021, 20(05): 427-433.